Chitin-glucan improves important pathophysiological features of irritable bowel syndrome

Area of Science:

• Gastroenterology
• Nutritional Science
• Molecular Biology

Background:

• Irritable Bowel Syndrome (IBS) is a prevalent condition with limited effective treatments.
• Chitin-glucan (CG), a novel dietary prebiotic, is safe for human consumption.
• Preclinical studies evaluated CG's potential in addressing IBS pathophysiology.

Purpose of the Study:

• To assess CG's efficacy in visceral analgesia and reducing intestinal inflammation.
• To investigate CG's impact on intestinal barrier function.
• To develop computational molecular models of CG's interactions.

Main Methods:

• Visceral pain and hypersensitivity were modeled in rats using colorectal distension (CRD) and TNBS induction.
• Anti-inflammatory effects were assessed in mice with DSS-induced colitis.
• Cellular assays (HT-29) evaluated CG's effects on pain, inflammation, and barrier genes via real-time PCR.
• Molecular modeling and simulations were used to analyze CG's interaction with microbial lipids.

Main Results:

• CG was well-tolerated and did not induce adverse effects.
• CG significantly reduced visceral pain perception and inflammation in animal models.
• CG demonstrated superior or comparable efficacy to phloroglucinol in pain reduction.
• Molecular mechanisms included upregulation of opioid and cannabinoid receptors and IL-10, with downregulation of IL-1b and IL-8.
• CG enhanced intestinal barrier function by upregulating specific genes.
• Molecular modeling revealed CG's ability to chelate microbial pathogenic lipids like LPS and LTA.

Conclusions:

• Chitin-glucan (CG) effectively decreases visceral pain and intestinal inflammation.
• CG acts through regulating key genes involved in pain and inflammation pathways.
• CG's direct binding of microbial products offers a novel therapeutic mechanism for IBS.